-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Suckinumab has shown continued effectiveness and safety in several psoriasis symptoms, including nails, scalp, palms, soles and psoriatic arthritis
.
GRIGHT studied the long-term (2.
5 years) safety and effectiveness of subcutaneous injection of Suckinumab 150 and 300 mg in 205 patients with moderate to severe palmoplantar psoriasis (PpPsO)
.
method:
GRIGHT studied the long-term (2.
5 years) safety and effectiveness of subcutaneous injection of Suckinumab 150 and 300 mg in 205 patients with moderate to severe palmoplantar psoriasis (PpPsO)
.
The 140-week study includes 4 phases: screening (up to 4 weeks), treatment phase 1 (TP1, 16 weeks), treatment phase 2 (TP2, 116 weeks), and post-treatment follow-up (8 weeks)
.
Eligible subjects were randomly received at a ratio of 1:1:1 to receive scocilizumab 150 mg, scocilizumab 300 mg or placebo
Subjects assigned to 150 or 300 mg of Skucilizumab were given once a week for the first 5 weeks, and then every 4 weeks from the 8th week to the 128th week (inclusive)
.
At the end of TP1 (week 16), subjects who did not respond to ppIGA in the placebo group (that is, subjects who did not reach 0 or 1 ppIGA, and were at least 2 points lower than baseline), were 1:1 The proportion was re-randomly divided into 150 or 300 mg of Skuchiyuumab
The results showed that the patient's relevant index (PpIGA) 0/1 reached the standard at the 16th week
.
The study time was 2.
The patient's related index (PpIGA) 0/1 reached the standard at the 16th week
Conclusion: GRIGURE is by far the largest and longest randomized controlled trial of ppPsO.
The results showed that Suckinumab provided a strong and sustained response during the 2.
5 years of challenging the treatment of ppPsO
.
The results show that Suckinumab has provided a strong and sustained response during the 2.
5 years of challenging the treatment of ppPsO
.
Literature source: Gottlieb AB, Kubanov A, van Doorn M, Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2.
Leave a message here
